Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
2.
Multiple Sclerosis Journal ; 27(2 SUPPL):271-272, 2021.
Article in English | EMBASE | ID: covidwho-1496034

ABSTRACT

Introduction: The COVID-19 pandemic has had a significant impact on research and health care in MS. This study-within-atrial (SWAT) takes place within a host trial investigating the feasibility of the Cognitive-Occupation-Based programme for people with MS (COB-MS) that was originally designed to be delivered in-person but was amended to an online environment. As such, reliable remote cognitive testing could provide safer and more convenient care for MS patients. Aims: The SWAT examines the reliability of delivering the Brief International Cognitive Assessment for MS (BICAMS) and the Trail-Making Test (TMT) remotely to people with MS. Objectives: Performance on BICAMS measures and the TMT administered remotely are compared with performance on tests administered in-person. BICAMS measures include the California Verbal Learning Test, Second Edition (CVLT-II), the Symbol Digit Modality Test (SDMT) and the Brief Visuospatial Memory Test-Revised (BVMT-R). Method: Independent samples t-tests were conducted on a sample of 68 participants to investigate differences in performance between Group 1 (11 males, 23 females), who were visited by a research assistant in their homes before the pandemic and Group 2 (10 males, 24 females) who received online testing only via teleconference platform Zoom. Within-group differences for Group 1 who also received virtual testing after a six-month interval were also examined. Results: The analysis revealed no significant differences in scores between virtual and in-person administrations of the CVLT-II, TMT and SDMT. Strong positive correlations were found for inperson and virtual tests within Group 1 after a six-month interval on the CVLT-II, SDMT, TMT-A and TMT-B. BVMT-R scores were significantly higher for virtual testing (M = 20.59, SD = 6.65) compared to in-person testing (M = 16.35, SD = 6.05). However, this discrepancy may be attributed to inter-rater differences, rather than enhanced performance for online testing. In-person and virtual assessments within Group 1 were also strongly correlated (r = .72). Conclusions: The findings support the reliability of remote administration of BICAMS and the TMT in people living with MS.

3.
Multiple Sclerosis Journal ; 27(2 SUPPL):724, 2021.
Article in English | EMBASE | ID: covidwho-1496003

ABSTRACT

Introduction: Traditionally, public and patient involvement (PPI) in research has included people with MS in consultation roles rather than deeper levels of 'involvement'. There has also been limited evidence regarding the impact that such involvement has on the person living with MS or on trials which employ people living with MS, as part of the research team. Here we report on the experiences of a person living with MS who is embedded in a clinical trial throughout the lifetime of the project- an embedded patient researcher (EPR). Aims & Objectives: The aim of this research is to explore and present an embedded patient researcher's (EPR) perspective on PPI integration within a feasibility trial of a Cognitive Occupation- Based programme for people living with MS (COB-MS), with respect to the PPI impact on trial feasibility and potential success. Methods: This presentation is focused on three specific examples of EPR impact, participant recruitment, trial materials and adapting to the impact of the SARS-Cov-2 pandemic on the trial. Due to the high level of PPI integration within COB-MS, significant amendments were made. Results: As a result of a high level of PPI integration, the research team identified the recruitment of between 34% - 62% of participants as a result EPR involvement, which also influenced the decision to extend the role of the EPR to include Patient Advocacy. The EPR's involvement facilitated the development of more accessible trial materials for participants with MS and the development of online protocols for the treatment and assessment of participants. Conclusion: When fully integrated into a trial, PPI - along with the inclusion of an EPR - has the potential to improve participant recruitment, trial material development and adaptability as a result of external factors impacting the trial (with respect to being more suitable for participants with MS.) It has also encouraged the EPR to develop further as a Patient Advocate, by sharing their experience with patients wanting to become more involved in research as well as researchers and educators who want to incorporate PPI in their research or training.

SELECTION OF CITATIONS
SEARCH DETAIL